C-level moves within drug discovery and development
We round-up the key senior career moves in the industry over the last few months.
Emile Shaffu, Director of Sales, Newcells Biotech: Shaffu has over 20 years of international sales and management experience in the life sciences, most recently as UK Regional Business Manager at Bionano Genomics. He also worked for five years at Horizon Discovery (now Revvity).
Amanda Mackenzie, Director of R&D Operations, Glen Clova Scientific: Mackwnzie has moved from a role as R&D Director at Keltic Pharma Therapeutics and has also held senior roles at BioAscent Discovery, Excellerate Bioscience and BASF.
Adam Rosenberg, Chair of the Board, VectorY Therapeutics: Rosenberg brings over 20 years of experience in building and leading life sciences companies, primarily in the neuroscience space. He replaces Dr Carlo Incerti who is stepping down from the company’s board.
Dr Stefan Hamill, VP of Strategy, SMi Systems: Hamill was formerly a senior analyst at investment banks Numis (now Deutsche Numis) and Peel Hunt. He was lead analyst for clients such as the life science research tools companies Abcam and Oxford Nanopore.
Antonin (Tony) de Fougerolles, Chair, etherna: de Fougerolles has served as an Independent Board Member since January 2023 and will also take an active consultancy role. He has nearly 25 years of biotech R&D experience, including as founding Chief Scientific Officer at Moderna Therapeutics and VP of Research at Alnylam.
Geoffrey Hodge, Non-Executive Director, Cellular Origins: Hodge was most recently CEO of SOTIO Biotech US and CTO of Unum Therapeutics. Prior to entering the cell therapy sector, Geoff co-founded Xcellerex, where he was the primary inventor of the XDR single-use bioreactor.
Dr Jonathan Appleby, Chief Scientific Officer, Mogrify: Appleby joins Mogrify from the Cell and Gene Therapy Catapult, where he was Executive Director and Chief Scientific Officer. Prior to this, Dr Appleby was CSO for Cell and Gene Therapy in GSK’s Rare Diseases Unit.
James Halle, Chief Commercial Officer, Optibrium: Halle joins Optibrium from Cytel, a clinical trials services and software business, where as the Global Head of Product Growth, he led the software division’s global commercial team. He previously held a range of leadership positions at IQVIA.
Dr Eric Adam, Chief Operating Officer, and Dr Jordan Shin, Chief Medical Officer, HAYA Therapeutics: Adam joins after serving as Global Head of Operations within Neuroscience and Rare Diseases in Pharma Research and Early Development (pRED) at Roche. Shin most recently worked as Senior Vice President of Clinical Development and Translational Science, Cardiology at LEXEO Therapeutics.
Dr Chris Mathes, Chief Commercial Officer, Metrion Biosciences: Mathes has over 25 years of experience in the biopharmaceutical sector, recently in executive-level positions at Sophion Bioscience, ChanTest (now part of Charles River Laboratories), Icagen and AnaBios.
Paula Brown Stafford, Chief Executive Officer, Allucent: Stafford formerly served as the President of Clinical Development at Quintiles (now IQVIA) and as the President, CEO and Chairman of Novan, a clinical development-stage biotechnology company.
Steve Becker, Chief Commercial Officer, Broken String Biosciences: Becker joins from Thermo Fisher Scientific, and has held executive level or leadership positions at Quest Diagnostics, Athena Diagnostics, RainDance Technologies, Agilent Technologies and GE Healthcare.
Raees Ebrahim, Vice President of Sales, Arima Genomics: Ebrahim was Vice President of Sales at ChromaCode, and previously held senior leadership roles at Preferred Medicine, BioReference Laboratories, Sound Physicians, and Natera.
Dr Cynthia Wat, Chief Medical Officer, AiCuris: Wat has worked on licensed products such as Fuzeon, Pegasys, and Tamiflu at Roche and is a recognised expert in infectious diseases with experience in a range of therapeutic modalities.
Lori Ball, Chief Executive Officer, Astoriom: Prior to joining Astoriom, Ball was President and Chief Executive Officer at StageBio, a preclinical and clinical histology, pathology, image analysis, and specimen archiving services provider.
Iskra Reic, Independent Director, myTomorrows: Reic leads AstraZeneca’s global Vaccines & Immune Therapies unit, and previously held a variety of global leadership roles, including leading the company’s Europe and Canada business.
Jade Dagher, General Manager for Canada, Sygnature Discovery: Dagher has over 35 years of experience in pharmaceuticals, including 25 years with Merck. He moves from a role as General Manager in Northwestern Europe and Canada for Roche Diabetes Care.
Russell Abberley, Acting President, Association of the British Pharmaceutical Industry (ABPI):Abberley is General Manager of Amgen UK and Ireland. He has served on the ABPI Board since July 2020, and was part of the industry Negotiating Team for the 2024 Voluntary Agreement for Pricing, Access and Growth scheme.
Dr Manasi Sinha Jaiman, Chief Medical Officer and Dr Tom Bicsak, Head of Regulatory Affairs, Aardvark Therapeutics: Jaiman was Vice President at Vertex Pharmaceuticals and Chief Medical Officer of ViaCyte where she developed novel approaches in cell therapy. Bicsak previously worked at Biosplice, Elcelyx, Orexigen, Amylin, Dura, and Johnson & Johnson.
Luba Greenwood, Chair, Board of Directors, Closed Loop Medicine: Greenwood is currently the Managing Partner of Binney Street Capital (BSC), a venture fund she founded at the Dana-Farber Cancer Institute and has previously served as CEO and Chair of Kojin Therapeutics.
Dr Alex Dickinson, Non-Executive Director, Sphere Fluidics: Dickinson was Senior Vice President of Strategic Initiatives at Illumina. He joined Illumina through the acquisition of Helixis, which he co-founded and led as CEO. He was also the Founder and CEO of Luxtera.
Annabella Amatulli, Head of Regulatory Affairs, Enterprise Therapeutics: Amatulli was previously Head of Global Regulatory Sciences at Alfasigma, and has led interactions with health authorities including EMA, FDA, MHRA and NMPA to obtain Orphan Drug Designation, Fast Track and Breakthrough approvals.
Diana Spencer, Senior Digital Content Editor, DDW
